# Efficacy and Safety of Daratumumab in Combination With Bortezomib, Thalidomide, and Dexamethasone Regimens in Newly Diagnosed Multiple Myeloma

> **NCT05561049** · — · UNKNOWN · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 120 (estimated)

## Conditions studied

- Newly Diagnosed Multiple Myeloma

## Interventions

- **DRUG:** Daratumumab in Combination with Bortezomib, Thalidomide, and Dexamethasone Regimens

## Key facts

- **NCT ID:** NCT05561049
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10-01
- **Primary completion:** 2024-09-30
- **Final completion:** 2025-09-30
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2022-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05561049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05561049, "Efficacy and Safety of Daratumumab in Combination With Bortezomib, Thalidomide, and Dexamethasone Regimens in Newly Diagnosed Multiple Myeloma". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT05561049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*